By FarmaKology

FarmaKology-4th COVID vaccine dose offers “marginal benefits” in healthy adults





Subscribe to our newsletter

By subscribing, you agree with Revue’s Terms of Service and Privacy Policy and understand that FarmaKology will receive your email address.



March 18 · Issue #100 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+15K Subscribers )!

FarmaKology-4th COVID vaccine dose offers “marginal benefits” in healthy adults
FarmaKology-4th COVID vaccine dose offers “marginal benefits” in healthy adults
Novo Banking
Novo Banking
Today's Company
Flare Therapeutics
Flare Therapeutics
Flare Therapeutics
Flare Therapeutics is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.
Today marks a major milestone for EUROAPI, a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients* (API), as Sanofi’s Board of Directors unanimously proposed, on March 17th, to submit to its shareholders the distribution of circa 58% of the share capital of EUROAPI. In addition to the previously proposed €3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval at Sanofi’s May 3, 2022 Ordinary and Extraordinary Shareholders’ Meeting.
Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek’s industry-leading 3D printing and digital pharmaceutical technologies and Siemens’ global leadership in automation and digitization is expected to lead to innovative and transformative solutions for the development and manufacturing of pharmaceuticals.
 Viatris Inc. announced that it is pleased with the decision by the United States Court of Appeals for the Federal Circuit denying Biogen’s request that the Court reconsider its prior decision affirming the invalidity of Biogen’s U.S. Patent No. 8,399,514, covering Tecfidera®. Following the Court’s denial of Biogen’s rehearing petition, the ‘514 patent remains invalid. Viatris’ subsidiary Mylan Pharmaceuticals, Inc.
Simcere and Lynk Pharmaceuticals Co., Ltd. announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China. Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to market LNK01001 for the indications of rheumatoid arthritis and ankylosing spondylitis in China, after completing the payment of all commercialization rights and interests.
Research & Study
Stream Tackling drug development with Mike Rea by The MedTalk Podcast | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar
How Big Pharma is Extending the Pandemic
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue